☆ 4.5 Article

Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial

JOURNAL OF HEADACHE AND PAIN (2022)

Related references

Note: Only part of the references are listed.

Article Clinical Neurology

Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score

Luigi Francesco Iannone et al.

Summary: This study evaluated the effectiveness and safety of three monoclonal antibodies against the calcitonin gene-related peptide pathway (erenumab, galcanezumab, and fremanezumab) in patients with resistant chronic migraine. The results showed that all three anti-CGRP mAbs were effective and safe, with a high percentage of patients achieving a ≥ 50% reduction in Migraine Disability Assessment (MIDAS) score.

CNS DRUGS (2022)

Add to Collection

Article Clinical Neurology

Predictors of sustained response and effects of the discontinuation of anti-calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine

Luigi Francesco Iannone et al.

Summary: This study evaluated the effects of discontinuation and retreatment of anti-CGRP mAbs in resistant chronic migraine patients and found that most patients experienced worsening of symptoms during the 3-month discontinuation period, which was rapidly resolved by retreatment. However, a quarter of patients showed sustained benefit during discontinuation and did not require retreatment.

EUROPEAN JOURNAL OF NEUROLOGY (2022)

Add to Collection

Article Clinical Neurology

Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3-month observational, longitudinal, cohort, multicenter, Italian real-life study

Fabrizio Vernieri et al.

Summary: This study found that in patients with chronic migraine, unilateral pain, a good response to triptans, and normal weight may be associated with a persistent positive response in the first 3 months of therapy with galcanezumab.

EUROPEAN JOURNAL OF NEUROLOGY (2022)

Add to Collection

Article Clinical Neurology

linic and genetic predictors in response to erenumab

Chiara Zecca et al.

Summary: In this study, treatment with ERE significantly reduced MMDs in migraine patients. Factors such as age at migraine onset, number of failed preventive medications, and migraine burden were found to influence the response to ERE. The study also suggested a potential role for RAMP1 rs7590387 as a genetic predictor of ERE efficacy.

EUROPEAN JOURNAL OF NEUROLOGY (2022)

Add to Collection

Article Clinical Neurology

A real-world, observational study of erenumab for migraine prevention in Canadian patients

Werner J. Becker et al.

Summary: This study assessed the real-world effectiveness, safety, and usage of erenumab in Canadian patients with previous ineffective prophylactic treatments for migraine. The results showed that one-third of patients experienced a reduction of >= 50% in monthly migraine days after using erenumab for 3 months.

HEADACHE (2022)

Add to Collection

Review Clinical Neurology

European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention-2022 update

Simona Sacco et al.

Summary: This guideline evaluated the effectiveness and safety of monoclonal antibodies targeting the CGRP pathway for migraine prevention through systematic review and literature analysis, and provided updated treatment recommendations.

JOURNAL OF HEADACHE AND PAIN (2022)

Add to Collection

Review Clinical Neurology

The importance of an early onset of migraine prevention: an evidence-based, hypothesis-driven scoping literature review

Christopher Gottschalk et al.

Summary: This review study analyzes clinical trial data and finds that some approved migraine preventive therapies can bring significant improvements in the early stages of treatment, such as reducing the frequency and severity of migraine attacks. However, the available evidence for early onset prevention of migraine is limited.

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2022)

Add to Collection

Article Clinical Neurology

Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial

Messoud Ashina et al.

Summary: This study found that treatment with erenumab led to a reduction in migraine frequency, improvement in health-related quality of life, and these effects were maintained for at least 5 years. No new safety signals were observed during the 5 years of exposure.

EUROPEAN JOURNAL OF NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study

Piero Barbanti et al.

Summary: Erenumab 70 mg is effective, safe, and well tolerated in real life. Easily obtainable clinical features might be of help in predicting patient's responsiveness.

HEADACHE (2021)

Add to Collection

Article Clinical Neurology

Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study

Fabrizio Vernieri et al.

Summary: The study aimed to evaluate the effect of discontinuing mAbs anti-CGRP on migraine patients. Results showed that migraine frequency and disability gradually increased after stopping the treatment, but most patients did not relapse to medication overuse or chronic migraine.

JOURNAL OF HEADACHE AND PAIN (2021)

Add to Collection

Meeting Abstract Clinical Neurology

Persistence, use of resources and costs in patients who start preventive medication for the treatment of migraine in Spain: The persec study

Pablo Irimia et al.

JOURNAL OF THE NEUROLOGICAL SCIENCES (2021)

Add to Collection

Article Clinical Neurology

Erenumab for Migraine Prevention in a 1-Year Compassionate Use Program: Efficacy, Tolerability, and Differences Between Clinical Phenotypes

Jean Schoenen et al.

Summary: During a 1-year compassionate use program, 156 patients with migraine self-administered a monthly dose of erenumab 140 mg with a subcutaneous autoinjector. The drug showed significant efficacy in reducing monthly headache days, headache severity, and days with acute drug intake. Adverse effects were generally mild, with constipation being the most frequent. The therapeutic effect was maintained over 12 months, with higher responder rates in patients with episodic migraine compared to chronic migraine.

FRONTIERS IN NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Gender Differences in 3-Month Outcomes of Erenumab Treatment-Study on Efficacy and Safety of Treatment With Erenumab in Men

Raffaele Ornello et al.

Summary: The study found that erenumab is equally safe and effective in men compared with women after 12 weeks, without gender differences observed in the outcomes.

FRONTIERS IN NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)

Fabrizio Vernieri et al.

Summary: In real-life settings, galcanezumab showed significant effectiveness in preventing HFEM and CM by reducing the number of migraine days and headache intensity, with good safety and tolerability. Patients who responded well to galcanezumab tended to have normal weight and a history of fewer failed preventive treatments.

JOURNAL OF HEADACHE AND PAIN (2021)

Add to Collection

Article Clinical Neurology

Long-term Efficacy and Safety of Erenumab Results From 64 Weeks of the LIBERTY Study

Peter J. Goadsby et al.

Summary: In patients with episodic migraine who were unsuccessful on 2 to 4 preventive treatments, erenumab monotherapy demonstrated sustained efficacy through 64 weeks, and the safety profile observed was consistent with previous clinical trials.

NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Refractory migraine profile in CGRP-monoclonal antibodies scenario

Marcello Silvestro et al.

Summary: Patients with refractory migraine who do not respond to CGRP-mAbs treatment show higher baseline frequency of migraine attacks, medication overuse, and pain catastrophizing. Olanzapine treatment was effective in reducing headache days/month in 67% of patients who did not respond to CGRP-mAbs, supporting the hypothesis of dopaminergic pathway involvement in migraine refractoriness.

ACTA NEUROLOGICA SCANDINAVICA (2021)

Add to Collection

Article Clinical Neurology

Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study

Piero Barbanti et al.

Summary: In a real-world setting, erenumab showed long-term effectiveness, safety, and tolerability in patients with high-frequency episodic migraine or chronic migraine with multiple prior preventive treatment failures. Positive predictors of responsiveness included allodynia in high-frequency episodic migraine, male sex, and baseline migraine frequency in chronic migraine, while negative predictors included psychiatric comorbidities and prior treatment failures in chronic migraine patients.

HEADACHE (2021)

Add to Collection

Article Clinical Neurology

The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice

Jessica Ailani et al.

Summary: This update aims to incorporate recent research findings, expert consensus, and patient perspectives into updated guidance on the use of new acute and preventive treatments for migraine in adults. It provides practical recommendations based on expanded evidence base and emerging expert consensus, in the absence of a formal guideline.

HEADACHE (2021)

Add to Collection

Article Behavioral Sciences

Predictors of response to erenumab after 12 months of treatment

Carlo Baraldi et al.

Summary: This study aimed to identify clinical predictors of good response in patients with chronic migraine and medication overuse-headache treated with erenumab. After 1 year, significant improvements were observed in headache days, analgesic consumption, headache impact tests, and migraine disability assessment questionnaire scores compared to baseline. Patients with longer medication overuse-headache duration, higher analgesic intake, and more previous failed preventive treatments may receive less benefit with erenumab.

BRAIN AND BEHAVIOR (2021)

Add to Collection

Article Clinical Neurology

Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study

Stewart J. Tepper et al.

CEPHALALGIA (2020)

Add to Collection

Article Clinical Neurology

Neurophysiological and biomolecular effects of erenumab in chronic migraine: An open label study

Roberto De Icco et al.

CEPHALALGIA (2020)

Add to Collection

Article Clinical Neurology

European headache federation consensus on the definition of resistant and refractory migraine Developed with the endorsement of the European Migraine & Headache Alliance (EMHA)

Simona Sacco et al.

JOURNAL OF HEADACHE AND PAIN (2020)

Add to Collection

Article Clinical Neurology

A prospective real-world analysis of erenumab in refractory chronic migraine

Giorgio Lambru et al.

JOURNAL OF HEADACHE AND PAIN (2020)

Add to Collection

Article Clinical Neurology

CGRP and headache: a brief review

Stewart J. Tepper

NEUROLOGICAL SCIENCES (2019)

Add to Collection

Article Clinical Neurology

Erenumab in chronic migraine Patient-reported outcomes in a randomized double-blind study

Richard B. Lipton et al.

NEUROLOGY (2019)

Add to Collection

Review Pharmacology & Pharmacy

New Trends in Migraine Pharmacology: Targeting Calcitonin Gene-Related Peptide (CGRP) With Monoclonal Antibodies

Damiana Scuteri et al.

FRONTIERS IN PHARMACOLOGY (2019)

Add to Collection

Article Pharmacology & Pharmacy

Cost-Effectiveness Analysis of Erenumab Versus OnabotulinumtoxinA for Patients with Chronic Migraine Attacks in Greece

Theodoros V. Giannouchos et al.

CLINICAL DRUG INVESTIGATION (2019)

Add to Collection

Review Medicine, General & Internal

Targeting calcitonin gene-related peptide: a new era in migraine therapy

Andrew Charles et al.

LANCET (2019)

Add to Collection

Article Clinical Neurology

Migraine Epidemiology, Burden, and Comorbidity

Rebecca C. Burch et al.

NEUROLOGIC CLINICS (2019)

Add to Collection

Article Clinical Neurology

European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

Simona Sacco et al.

JOURNAL OF HEADACHE AND PAIN (2019)

Add to Collection

Article Clinical Neurology

Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults

Cristina Tassorelli et al.

CEPHALALGIA (2018)

Add to Collection

Article Clinical Neurology

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition

Jes Olesen

CEPHALALGIA (2018)

Add to Collection

Review Clinical Neurology

CGRP as the target of new migraine therapies - successful translation from bench to clinic

Lars Edvinsson et al.

NATURE REVIEWS NEUROLOGY (2018)

Add to Collection

Article Clinical Neurology

Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial

Stewart Tepper et al.

LANCET NEUROLOGY (2017)

Add to Collection

Article Clinical Neurology

Cost of Chronic and Episodic Migraine: a pilot study from a tertiary headache centre in northern Italy

E. Berra et al.

JOURNAL OF HEADACHE AND PAIN (2015)

Add to Collection

Article Clinical Neurology

Adherence to oral migraine-preventive medications among patients with chronic migraine

Zsolt Hepp et al.

CEPHALALGIA (2015)

Add to Collection

Article Computer Science, Interdisciplinary Applications

nparLD: An R Software Package for the Nonparametric Analysis of Longitudinal Data in Factorial Experiments

Kimihiro Noguchi et al.

JOURNAL OF STATISTICAL SOFTWARE (2012)

Add to Collection

Article Anesthesiology

Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers

WF Stewart et al.

PAIN (2000)

Add to Collection

© Peeref 2019-2024. All rights reserved.